💊 Medicamentos A-Z 🧬 Alvos 🛠 Ferramentas 📚 Guias
Todos os Medicamentos Classes de Medicamentos Áreas Terapêuticas Efeitos Colaterais
Guias Glossário Linha do Tempo
Comparações Percursos de Medicamentos Famílias de Medicamentos
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Technetium Tc 99M Pyrophosphate

CHEMBL1200333 Phase 4 Aprovado Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
272.8 g/mol
LogP
—
Phase
4

Technetium Tc 99m pyrophosphate is a radiolabeled bone and cardiac imaging agent that has become the preferred non-invasive scintigraphic test for diagnosing transthyretin cardiac amyloidosis (ATTR-CA), where it accumulates in amyloid-laden myocardium. See technetium-pyrophosphate for complete pharmacological details. It is also used in standard bone scintigraphy and historically for infarct-avid myocardial imaging.

Peso Molecular

272,8500 g/mol

TPSA

136,00 Ų

Áreas Terapêuticas

Heart Failure

Mecanismo de Ação

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

SMILES

[O-]P(=O)([O-])OP(=O)([O-])[O-].[99Tc]

InChI

InChI=1S/H4O7P2.Tc/c1-8(2,3)7-9(4,5)6;/h(H2,1,2,3)(H2,4,5,6);/p-4/i;1+1

Molecular Formula

O7P2Tc-4

HBD / HBA

- / 7

Ligações Rotacionáveis

0

Átomos Pesados

10

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Technetium Tc 99m pyrophosphate is a radiolabeled bone and cardiac imaging agent that has become the preferred non-invasive scintigraphic test for diagnosing transthyretin cardiac amyloidosis (ATTR-CA), where it accumulates in amyloid-laden myocardium. See technetium-pyrophosphate for complete pharmacological details. It is also used in standard bone scintigraphy and historically for infarct-avid myocardial imaging.

Stabilizes the transthyretin (TTR) protein tetramer, preventing its dissociation into monomers that misfold and aggregate into amyloid fibrils in cardiac tissue.

Yes, Technetium Tc 99M Pyrophosphate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200333. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 155491164. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.